Research

Rhabdomyosarcoma Treatment with Combination Therapy - Phase III

Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma

Protocol Description

The goals of this Children's Oncology Group study are to see if a new combination of vincristine, dactinomycin and cyclophosphamide (VAC) plus an additional drug combination of vincristine and irinotecan (VI) is better for treatment of rhabdomyosarcoma than the standard chemotherapy (VAC) alone, and to compare the effects of this new combination. In addition, radiation therapy will be started earlier than the standard treatment regimen.

Eligibility Criteria

The multi-center group study accepts male and female candidates under age 50 who have been diagnosed with rhabdomyosarcoma.
Boys: All ages
Girls: All ages

Requirements
Participants will undergo standard medical and organ function tests and procedures throughout the length of this study. A central line will be recommended for all participants to aid in administering chemotherapy medicines.
Visits: Number of visits is variable depending on the patient’s response; some treatments may require hospitalization.
Duration: 43 weeks, with patients’ health monitored for an additional 10 years

Status: Open

Source of Support
Children’s Oncology Group (Study ARST0531)
National Cancer Institute

Additional Resources
Study Description at National Institutes of Health
Children’s Oncology Group CureSearch